EP1906976A4 - THERAPEUTIC POLYMERS AND METHODS OF USE - Google Patents

THERAPEUTIC POLYMERS AND METHODS OF USE

Info

Publication number
EP1906976A4
EP1906976A4 EP06760640A EP06760640A EP1906976A4 EP 1906976 A4 EP1906976 A4 EP 1906976A4 EP 06760640 A EP06760640 A EP 06760640A EP 06760640 A EP06760640 A EP 06760640A EP 1906976 A4 EP1906976 A4 EP 1906976A4
Authority
EP
European Patent Office
Prior art keywords
methods
therapeutic polymers
therapeutic
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06760640A
Other languages
German (de)
French (fr)
Other versions
EP1906976A2 (en
Inventor
William G Turnell
Zaza D Gomurashvili
Ramaz Katsarava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1906976A2 publication Critical patent/EP1906976A2/en
Publication of EP1906976A4 publication Critical patent/EP1906976A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G71/00—Macromolecular compounds obtained by reactions forming a ureide or urethane link, otherwise, than from isocyanate radicals in the main chain of the macromolecule
    • C08G71/04—Polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06760640A 2005-06-03 2006-06-02 THERAPEUTIC POLYMERS AND METHODS OF USE Withdrawn EP1906976A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68757005P 2005-06-03 2005-06-03
US75917906P 2006-01-13 2006-01-13
PCT/US2006/021395 WO2006132950A2 (en) 2005-06-03 2006-06-02 Therapeutic polymers and methods of use

Publications (2)

Publication Number Publication Date
EP1906976A2 EP1906976A2 (en) 2008-04-09
EP1906976A4 true EP1906976A4 (en) 2011-11-09

Family

ID=37498935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06760640A Withdrawn EP1906976A4 (en) 2005-06-03 2006-06-02 THERAPEUTIC POLYMERS AND METHODS OF USE

Country Status (5)

Country Link
EP (1) EP1906976A4 (en)
JP (1) JP2008542393A (en)
AU (1) AU2006255262A1 (en)
CA (1) CA2610745A1 (en)
WO (1) WO2006132950A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7273469B1 (en) 2003-12-31 2007-09-25 Advanced Cardiovascular Systems, Inc. Modified needle catheter for directional orientation delivery
JP5192384B2 (en) 2005-09-22 2013-05-08 メディバス エルエルシー Bis- (α-amino) -diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
WO2007112046A2 (en) * 2006-03-24 2007-10-04 Medivas, Llc Alkylene-dicarboxylate-containing biodegradable poly(ester amides) and methods of use
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
US20080200377A1 (en) * 2007-02-16 2008-08-21 Trollsas Mikael O Polymer particles
WO2009073814A2 (en) * 2007-12-06 2009-06-11 Medivas, Llc Oligo-ethylene glycol-based polymer compositions and methods of use
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
CN107922565B (en) * 2015-06-23 2022-01-04 菲吉乐科(加拿大)有限公司 Compositions comprising amino acid polymers and bioactive agents and methods of making the same
CN110804175B (en) * 2019-11-08 2021-05-14 中国科学院理化技术研究所 Antibacterial polyamino acid derivative or copolymer with alternating structure and preparation method thereof
US12577398B2 (en) 2019-11-12 2026-03-17 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
US20020071822A1 (en) * 2000-07-27 2002-06-13 Uhrich Kathryn E. Therapeutic polyesters and polyamides
EP1945682A2 (en) * 2005-10-21 2008-07-23 Medivas, LLC Poly(ester urea) polymers and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430501A1 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
AU2003277023B2 (en) * 2002-09-26 2009-02-26 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
US20020071822A1 (en) * 2000-07-27 2002-06-13 Uhrich Kathryn E. Therapeutic polyesters and polyamides
EP1945682A2 (en) * 2005-10-21 2008-07-23 Medivas, LLC Poly(ester urea) polymers and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAURO A.M CARAI ET AL: "Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into [gamma]-hydroxybutyric acid", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 441, no. 3, 1 April 2002 (2002-04-01), pages 157 - 163, XP055008078, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(02)01502-9 *
SCHMELTZER R C ET AL: "Synthesis and cytotoxicity of salicylate-based poly(anhydride esters)", BIOMACROMOLECULES, ACS, WASHINGTON, DC, US, vol. 6, no. 1, 1 January 2005 (2005-01-01), pages 359 - 367, XP002482507, ISSN: 1525-7797, [retrieved on 20041126], DOI: 10.1021/BM049544+ *
WOO G L Y ET AL: "Synthesis and characterization of a novel biodegradable antimicrobial polymer", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 12, 1 June 2000 (2000-06-01), pages 1235 - 1246, XP004195834, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(00)00003-X *

Also Published As

Publication number Publication date
AU2006255262A1 (en) 2006-12-14
CA2610745A1 (en) 2006-12-14
WO2006132950A2 (en) 2006-12-14
JP2008542393A (en) 2008-11-27
EP1906976A2 (en) 2008-04-09
WO2006132950A3 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
EP1879626A4 (en) AMPHIPHILIC POLYMERS AND METHODS OF USE
EP1706791A4 (en) PHOTORESIN COMPOSITIONS AND METHODS OF USE
EP1812102A4 (en) OCCLUSAL ENDOPROTHESIS AND METHODS OF USE THEREOF
EP1855833A4 (en) PLASMAS AND METHODS OF USE
FR20C1033I1 (en) ANTI-CD79B ANTIBODIES, IMMUNO-CONJUGATES AND METHODS OF USE
EP1937268A4 (en) INDENOISOQUINOLINONE ANALOGUES AND METHODS OF USE
EP1831207A4 (en) AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
FR13C0045I2 (en) INACTIVE CHIMERAL VACCINES AND THEIR METHODS OF USE
EP2129313A4 (en) SURGICAL DEVICES AND METHODS OF USE
EP1996020A4 (en) PURIC COMPOUNDS AND METHODS OF USE
EP2170393A4 (en) ANTITHROMBOTIC AGENTS AND METHODS OF USE
EP1838331A4 (en) ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF
EP2046413A4 (en) MEDICAL SYSTEMS AND METHODS OF USE
EP1913112A4 (en) SUPPORTING AGENT AND METHODS OF USE
EP2124831A4 (en) PROSTHETIC DEVICES AND METHODS OF USE
MA30684B1 (en) ANTI-MN ANTIBODIES AND METHODS OF USE THEREOF
MA29029B1 (en) THIADIAZOLE COMPOUNDS AND METHODS OF USE
EP2049559A4 (en) ENHANCED VACCINES AND METHODS OF USE
EP1804675A4 (en) IMPROVED COMBINED SENSORS, CORRESPONDING WIRE-GUIDE AND METHODS OF USE
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
EP1638977A4 (en) SALINOSPORAMIDES AND METHODS OF USE
EP1933884A4 (en) IMAGING AGENTS AND METHODS OF USE
EP1795004A4 (en) IMAGING ARRANGEMENTS AND ASSOCIATED METHODS
EP1723227A4 (en) NICOTINAMIDE RIBOSIDE KINASE COMPOSITIONS AND METHODS OF USE
EP2066817A4 (en) MOLECULAR SWITCHES AND METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071228

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111011

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/02 20060101ALI20111005BHEP

Ipc: A61K 31/785 20060101ALI20111005BHEP

Ipc: C08L 77/00 20060101AFI20111005BHEP

Ipc: A61K 9/16 20060101ALI20111005BHEP

Ipc: A61K 9/51 20060101ALI20111005BHEP

Ipc: C08G 18/10 20060101ALI20111005BHEP

Ipc: C12N 15/88 20060101ALI20111005BHEP

Ipc: A61K 47/34 20060101ALI20111005BHEP

Ipc: C08G 69/44 20060101ALI20111005BHEP

Ipc: C08L 77/12 20060101ALI20111005BHEP

Ipc: A61K 47/48 20060101ALI20111005BHEP

Ipc: A61K 48/00 20060101ALI20111005BHEP

Ipc: A61K 9/50 20060101ALI20111005BHEP

Ipc: C07K 16/28 20060101ALI20111005BHEP

Ipc: A61K 9/107 20060101ALI20111005BHEP

Ipc: A61F 2/00 20060101ALI20111005BHEP

Ipc: C08L 75/06 20060101ALI20111005BHEP

Ipc: C08L 75/04 20060101ALI20111005BHEP

Ipc: A61L 31/00 20060101ALI20111005BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120508